International Journal of Urology最新文献

{"title":"Editorial Comment on the Correlation Between Discrepancies in Clinical and Pathological T Stages and Overall Survival in Upper Urinary Tract Urothelial Carcinoma: Analysis of the Hospital-Based Cancer Registry Data in Japan.","authors":"Akihito Hashizume","doi":"10.1111/iju.70039","DOIUrl":"https://doi.org/10.1111/iju.70039","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply: Is Seated Voiding Associated With Lower Urinary Tract Symptoms, Health Conditions, or Marital Status? Findings by Age Group From the 2023 Japan Community Health Survey.","authors":"Noritoshi Sekido, Nobuhiro Haga, Kenji Omae, Yasue Kubota, Takahiko Mitsui, Naoya Masumori, Motoaki Saito, Ryuji Sakakibara, Mikako Yoshida, Satoru Takahashi","doi":"10.1111/iju.70043","DOIUrl":"https://doi.org/10.1111/iju.70043","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An overview of renorrhaphy techniques for partial nephrectomy.","authors":"David Homewood, Nicholas Tan, Tayla Fay, Andrew Silagy, Nathan Lawrentschuk, Niall M Corcoran, Dinesh K Agarwal","doi":"10.1111/iju.15658","DOIUrl":"https://doi.org/10.1111/iju.15658","url":null,"abstract":"<p><p>Partial nephrectomy aims to provide both effective oncological management and renal function preservation. Surgical complications pertaining to the defect created during a partial nephrectomy include hemorrhage and urinary leak. Over time, approaches have advanced for managing the defect created during a partial nephrectomy. Herein, we explore techniques used for renorrhaphy in partial nephrectomy, its evolution and current state. We review the history of partial nephrectomy and the early techniques used to close the parenchymal defect, highlighting their advantages and disadvantages. The article then investigates the principles of renorrhaphy and the sliding clip technique. Modifications made to the sliding clip technique are depicted with illustrations. Single-layer versus double-layer closure and continuous versus interrupted sutures are evaluated. Non-renorrhaphy techniques, such as sealants and glues, used to seal the renal remnant are explored. By examining the evolution of renorrhaphy techniques, this article provides a comprehensive understanding of the improvements made in a key component of partial nephrectomy. We aim to provide novel insights towards better understanding the history and current state of renorrhaphy techniques in partial nephrectomy.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Essential Japanese Guidelines for the Prevention of Perioperative Infections in the Urological Field: 2023 Edition.","authors":"Katsumi Shigemura, Jun Kamei, Kazuyoshi Shigehara, Takuhisa Nukaya, Toshiki Etani, Yoshikazu Togo, Shingo Yamamoto","doi":"10.1111/iju.70026","DOIUrl":"https://doi.org/10.1111/iju.70026","url":null,"abstract":"<p><p>Recently, urological surgery has undergone remarkable technological advances and these new technologies are being adapted to a wide array of medical fields. Robotic-assisted laparoscopic procedures are not limited to radical prostatectomy, but include partial nephrectomy, pyeloplasty, radical cystectomy, and more. Perioperative infection control measures are not limited to the selection, method, and duration of antimicrobials, but include new evidence about smoking cessation, abstinence from alcohol, blood glucose control, and nutritional status assessment as well as time off just before operations. The new 2023 JUA guidelines for the prevention of perioperative infections in the urological field include general remarks and itemized discussion. We chose three standard treatments related to background questions and nine clinical questions. Although we have organized information to the best of our ability, there are still many areas where evidence is lacking. We anticipate that urology specialists will continue to report new findings and accumulate more evidence regarding unresolved areas for the next revision.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Preferences for Post-Radical Cystectomy Treatment in Muscle-Invasive Bladder Cancer: A Discrete Choice Experiment in Japan.","authors":"Shugo Yajima, Shinro Hata, Naoya Masumori, Yoh Matsuoka, Atsuro Sawada, Jun Miki, Mitsuhiro Tambo, Yasuyuki Kobayashi, Ayumu Matsuda, Keita Nakane, Takashi Kobayashi, Hajime Tanaka, Noriya Yamaguchi, Go Kaneko, Russell Miller, Takehiro Seto, Hiroaki Ito, Eiji Kikuchi","doi":"10.1111/iju.70032","DOIUrl":"https://doi.org/10.1111/iju.70032","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the treatment preferences of Japanese patients with muscle-invasive bladder cancer (MIBC) by quantifying their trade-offs between treatment attributes using a discrete choice experiment (DCE).</p><p><strong>Methods: </strong>A DCE was conducted among MIBC patients post-radical cystectomy. Participants were presented with hypothetical treatment options differing in attributes such as efficacy Disease-free survival (DFS), side effects, administration, and cost. Preference data were analyzed to determine each attribute's relative importance (RI), maximum acceptable risk (MAR), and willingness to trade efficacy (WTTE).</p><p><strong>Results: </strong>Out of 105 patients surveyed, 101 were included in the final analysis. The DCE revealed that DFS had the highest RI (30.3%), followed by annual treatment cost (27.7%) and risk of severe side effects (26.8%). While MAR analysis indicated that patients were willing to accept some increase in side effects risk for significant gains in DFS, WTTE results showed a sensitivity to side effect severity and treatment costs, with patients often willing to trade off DFS for improvements in risks and costs. In subgroup analyses, such as pathological stage, age, and employment status, the trends for each subgroup were the same as those of the overall population. However, the magnitude of RI varied among patients with different characteristics. For example, younger patients preferred short-term treatment duration over longer, employed patients tended to favor long-term treatment duration.</p><p><strong>Conclusions: </strong>This study is the first to demonstrate the treatment preferences of Japanese MIBC patients who underwent radical cystectomy, and these results can inform treatment selection based on patient preferences.</p><p><strong>Trial registration: </strong>Japan Registry of Clinical Trials: jRCT1030220680.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T1b Renal Masses Radiofrequency Ablation: Feasibility, Safety, and Efficacy in Midterm Follow-Up.","authors":"Demian Jungklaus Travesso, Rayssa Araruna Bezerra de Melo, Maria Fernanda Arruda Almeida, Joaquim Maurício Motta-Leal-Filho, Eduardo Batista Soares Moura, Fabrício Machado","doi":"10.1111/iju.70042","DOIUrl":"https://doi.org/10.1111/iju.70042","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Second Resection Following Conventional Initial Transurethral Resection of Bladder Tumors.","authors":"Song Xu, Hongjie Shi, Fang Yu, Mengxin Lu, Zhonghua Yang, Hang Zheng","doi":"10.1111/iju.70041","DOIUrl":"https://doi.org/10.1111/iju.70041","url":null,"abstract":"<p><strong>Objectives: </strong>To determine the outcomes of the second transurethral resection of bladder tumors.</p><p><strong>Methods: </strong>Patients with bladder cancer who accepted both initial and second resections in our center from January 2021 to March 2024 were included. Tumor residue in the second resection and short-term oncological outcomes were determined. Multivariate analysis was performed to identify predictive factors for them.</p><p><strong>Results: </strong>A total of 125 patients were included. Tumor residue and upstaging were confirmed in 15 (12%) and in 1 (0.8%) patient, respectively. A younger age and a longer time (> 6w) to second resection were associated with a higher tumor residual rate (p < 0.05), and they were confirmed as predictors for tumor residue. Differences were not determined between patients with different tumor characteristics (e.g., Ta vs. T1). A median follow-up of 14 (3-40) months was conducted in 100 patients. Intravesical recurrence and progression were determined in 14 (14%) and 4 (4%) patients, with the 1-year recurrence-free and progression-free survivals of 86.5% and 96.9%, respectively. Maintenance BCG therapy was identified as a predictor for tumor recurrence (HR = 6.168, p < 0.05).</p><p><strong>Conclusions: </strong>A lower tumor residual rate than previously reported was achieved with acceptable short-term oncological outcomes after conventional transurethral resection of bladder tumors. The basis of second resection may need further exploration. Second resection may be prioritized for younger patients and performed within 6 weeks of the initial resection. Maintenance BCG therapy could reduce tumor recurrence after second resection.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between Restless Legs Syndrome and Overactive Bladder: A Cross-Sectional, Controlled Study.","authors":"Caner Moral, Mustafa Aydın, Ahmet Yılmaz, Lokman İrkılata, Alper Bitkin, Mustafa Koray Kırdağ, Mustafa Kemal Atilla","doi":"10.1111/iju.70036","DOIUrl":"https://doi.org/10.1111/iju.70036","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to investigate the common mechanisms in restless legs syndrome (RLS) and overactive bladder (OAB), the prevalence of OAB in RLS, and the effects of RLS treatment on OAB.</p><p><strong>Methods: </strong>Sixty patients newly diagnosed with RLS and 60 healthy individuals in the control group were included in the study. The patients completed the RLS-Severity Rating Scale and were started on pramipexole for treatment. Patients diagnosed with RLS were examined by the same physician for differential diagnosis, and urinalysis, urination diary, and ultrasonography were performed. All patients completed the AAM-V8 form, validated in Turkish, before and after treatment. The treatment effectiveness of the drug on the patients was evaluated using questioning forms.</p><p><strong>Results: </strong>No statistically significant difference was detected between gender and the average age of the patients and the control group (p = 0.540, p = 0.056). In the evaluation, a statistically higher rate of OAB was detected in the RLS group than in the control group (33.3%-13.3%, p < 0.01) and a positive correlation was observed between the severity of RLS symptoms and OAB-V8 scores. After RLS treatment, a statistically significant improvement was observed in the patients' OAB symptom scores compared to before treatment (p < 0.001).</p><p><strong>Conclusions: </strong>Our study revealed that the prevalence of OAB is higher in RLS than in the control group. Dopamine agonists used in the treatment of RLS may be useful as an alternative treatment option in the treatment of OAB, especially in certain patient groups who do not respond to standard treatment.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Analysis of the Enfortumab Vedotin-Ineligible criTeriA Assessment in Treatment-Naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma.","authors":"Makito Miyake, Nobutaka Nishimura, Yuki Oda, Takuto Shimizu, Kota Iida, Kiyohide Fujimoto","doi":"10.1111/iju.70040","DOIUrl":"https://doi.org/10.1111/iju.70040","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study.","authors":"Alicia K Morgans, Lisa Mucha, Christina Quicquaro, Vanessa Shih, Bin Xie, Christopher Young, Hongbo Yang, Qing Liu, Alexandra Greatsinger, Angela Lax","doi":"10.1111/iju.70023","DOIUrl":"https://doi.org/10.1111/iju.70023","url":null,"abstract":"<p><strong>Objective: </strong>To describe real-world patient characteristics, prior treatment patterns, and associated healthcare resource utilization (HRU) and costs among patients with locally advanced/metastatic urothelial carcinoma (la/mUC) treated with enfortumab vedotin (EV).</p><p><strong>Methods: </strong>This retrospective study used the United States (US) Centers for Medicare and Medicaid Services 100% Medicare claims data from 2015 to 2020. Included patients had a diagnosis of la/mUC and received treatment with EV. The index date was the EV initiation date. Endpoints included HRU and costs 12 months before the index date (baseline period) and treatment patterns before EV initiation. Results were summarized descriptively using means and standard deviations for continuous variables, and frequency counts and percentages for categorical variables.</p><p><strong>Results: </strong>Among the 529 included patients, the mean age at the time of EV initiation was 76.5 years. Most patients were White (88.1%) and male (77.1%). Common comorbidities were hypertension (85.1%), renal disease (65.2%), and peripheral vascular disease (42.5%). Platinum-based chemotherapy was the most frequent therapy two lines before EV initiation (43.9%). The most frequent therapy in the line before EV initiation was PD-1/L1 inhibitors (61.4%). The median duration of EV therapy was 4.1 months. The mean all-cause healthcare cost during the baseline period was $106 258 per patient, and 86% had at least one outpatient visit.</p><p><strong>Conclusions: </strong>This real-world study demonstrated that most US patients with la/mUC received platinum-based chemotherapy or a PD-1/L1 inhibitor prior to EV therapy from 2015 to 2020. HRU and costs 12 months before EV initiation suggest a substantial burden in this population. Long-term studies with more recent data are warranted.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}